| Product Name | IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIAL, IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIAL, IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL |
| Active Ingredient | Albutrepenonacog alfa(250IU/vial), Albutrepenonacog alfa(500IU/vial), Albutrepenonacog alfa(1000IU/Vial), Albutrepenonacog alfa(2000IU/vial) |
| Product Registrant | CSL BEHRING PTE. LTD. |
| Date of Approval | 26/12/2023 |
| Indications:Prophylaxis and treatment of bleeding in patients with haemophilia B (congenital factor IX deficiency) including control and prevention of bleeding in surgical settings. | |
| Product Name | TRELEGY ELLIPTA INHALATION POWDER 100 MCG/62.5 MCG/25 MCG |
| Active Ingredient | FLUTICASONE FUROATE (MICRONISED)(100 mcg),UMECLIDINIUM BROMIDE (MICRONISED) 74.2 MCG EQV TO UMECLIDINIUM(62.5 MCG),VILANTEROL TRIFENATATE (MICRONISED) 40 MCG EQV TO VILANTEROL(25 MCG) |
| Product Registrant | GLAXOSMITHKLINE PTE LTD |
| Date of Approval | 15/12/2023 |
| Indications:Trelegy Ellipta is indicated for the maintenance treatment of asthma in patients aged 18 years and older who are not adequately controlled with a combination of a long-acting beta2-agonist and an inhaled corticosteroid. | |
| Product Name | MENQUADFI SOLUTION FOR INJECTION |
| Active Ingredient | Meningococcal Polysaccharide, Serogroup A (Monovalent Conjugate) (10 mcg/ 0.5 mL), Meningococcal Polysaccharide, Serogroup C (Monovalent Conjugate) (10 mcg/ 0.5 mL), Meningococcal Polysaccharide, Serogroup W-135 (Monovalent Conjugate) (10 mcg / 0.5mL), Meningococcal Polysaccharide, Serogroup Y (Monovalent Conjugate) (10 mcg/ 0.5 mL), Tetanus Toxoid, Filtered Concentrate (Carrier Protein)(55 mcg/ 0.5 mL) |
| Product Registrant | SANOFI-AVENTIS SINGAPORE PTE. LTD. |
| Date of Approval | 21/12/2023 |
| Indications:MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. The use of this vaccine should be in accordance with available official recommendations. | |
| Product Name | JARDIANCE FILM-COATED TABLETS 10 MG |
| Active Ingredient | Empagliflozin 10 mg |
| Product Registrant | BOEHRINGER INGELHEIM SINGAPORE |
| Date of Approval | 26/12/2023 |
| Indications:JARDIANCE is indicated to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalisation in adults with chronic kidney disease at risk of progression. | |
HSA: Health Sciences Authority
Link to the HSA announcement: https://www.hsa.gov.sg/announcements/new-drug-indication-approvals/new-drug-indication-approval—december-2023
Only Authentic Products and Genuine Medical Supplies, at POM Marketplace!
Login or Register now to access our comprehensive range of medical supplies.
Disclaimer: The information provided on this page is intended solely for healthcare professionals for informational purposes only. While we strive for accuracy, POMConnect assumes no liability for errors or omissions. The content here should not be considered a substitute for professional medical advice. POMConnect does not endorse specific treatments or external websites linked from this page. Please note that the information is accurate at the time of publication and does not account for any modifications or updates made to the original research article after its initial publish date. POM Marketplace is accessible to qualified healthcare professionals only. Any unauthorized access or use by individuals who do not meet this criteria is prohibited.
